191 related articles for article (PubMed ID: 2164047)
1. Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer.
Takahashi T; D'Amico D; Chiba I; Buchhagen DL; Minna JD
J Clin Invest; 1990 Jul; 86(1):363-9. PubMed ID: 2164047
[TBL] [Abstract][Full Text] [Related]
2. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
3. Use of the single strand conformation polymorphism technique and PCR to detect p53 gene mutations in small cell lung cancer.
Hensel CH; Xiang RH; Sakaguchi AY; Naylor SL
Oncogene; 1991 Jun; 6(6):1067-71. PubMed ID: 1648702
[TBL] [Abstract][Full Text] [Related]
4. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S
Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410
[TBL] [Abstract][Full Text] [Related]
5. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
Bartek J; Iggo R; Gannon J; Lane DP
Oncogene; 1990 Jun; 5(6):893-9. PubMed ID: 1694291
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
Chiba I; Takahashi T; Nau MM; D'Amico D; Curiel DT; Mitsudomi T; Buchhagen DL; Carbone D; Piantadosi S; Koga H
Oncogene; 1990 Oct; 5(10):1603-10. PubMed ID: 1979160
[TBL] [Abstract][Full Text] [Related]
7. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors.
D'Amico D; Carbone D; Mitsudomi T; Nau M; Fedorko J; Russell E; Johnson B; Buchhagen D; Bodner S; Phelps R
Oncogene; 1992 Feb; 7(2):339-46. PubMed ID: 1312696
[TBL] [Abstract][Full Text] [Related]
8. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors.
Medina PP; Carretero J; Fraga MF; Esteller M; Sidransky D; Sanchez-Cespedes M
Genes Chromosomes Cancer; 2004 Oct; 41(2):170-7. PubMed ID: 15287030
[TBL] [Abstract][Full Text] [Related]
9. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.
Fong KM; Biesterveld EJ; Virmani A; Wistuba I; Sekido Y; Bader SA; Ahmadian M; Ong ST; Rassool FV; Zimmerman PV; Giaccone G; Gazdar AF; Minna JD
Cancer Res; 1997 Jun; 57(11):2256-67. PubMed ID: 9187130
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the p53 gene occur in diverse human tumour types.
Nigro JM; Baker SJ; Preisinger AC; Jessup JM; Hostetter R; Cleary K; Bigner SH; Davidson N; Baylin S; Devilee P
Nature; 1989 Dec; 342(6250):705-8. PubMed ID: 2531845
[TBL] [Abstract][Full Text] [Related]
12. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing.
Yu Q; Mirski SE; Sparks KE; Cole SP
Biochemistry; 1997 May; 36(19):5868-77. PubMed ID: 9153428
[TBL] [Abstract][Full Text] [Related]
13. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
[TBL] [Abstract][Full Text] [Related]
14. Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma.
Sameshima Y; Matsuno Y; Hirohashi S; Shimosato Y; Mizoguchi H; Sugimura T; Terada M; Yokota J
Oncogene; 1992 Mar; 7(3):451-7. PubMed ID: 1312700
[TBL] [Abstract][Full Text] [Related]
15. Splicing mutations of the p53 gene in human hepatocellular carcinoma.
Lai MY; Chang HC; Li HP; Ku CK; Chen PJ; Sheu JC; Huang GT; Lee PH; Chen DS
Cancer Res; 1993 Apr; 53(7):1653-6. PubMed ID: 8384081
[TBL] [Abstract][Full Text] [Related]
16. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern.
Takahashi T; Takahashi T; Suzuki H; Hida T; Sekido Y; Ariyoshi Y; Ueda R
Oncogene; 1991 Oct; 6(10):1775-8. PubMed ID: 1656362
[TBL] [Abstract][Full Text] [Related]
17. TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer.
Oh Y; Proctor ML; Fan YH; Su LK; Hong WK; Fong KM; Sekido YS; Gazdar AF; Minna JD; Mao L
Oncogene; 1998 Sep; 17(9):1141-8. PubMed ID: 9764824
[TBL] [Abstract][Full Text] [Related]
18. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium.
Lerman MI; Minna JD
Cancer Res; 2000 Nov; 60(21):6116-33. PubMed ID: 11085536
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer.
Sunahara M; Shishikura T; Takahashi M; Todo S; Yamamoto N; Kimura H; Kato S; Ishioka C; Ikawa S; Ikawa Y; Nakagawara A
Oncogene; 1999 Jun; 18(25):3761-5. PubMed ID: 10391684
[TBL] [Abstract][Full Text] [Related]
20. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data.
Lohmann D; Pütz B; Reich U; Böhm J; Präuer H; Höfler H
Am J Pathol; 1993 Mar; 142(3):907-15. PubMed ID: 8384408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
